Piper Jaffray Downgrades Hologic, Citing Competition from Roche's HPV Business | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray today downgraded Hologic amid anecdotal evidence suggesting Roche may be poised to take market share away from Hologic's sexually transmitted disease testing business.

Piper Jaffray lowered its rating for Bedford, Mass.-based Hologic to Neutral from Overweight and reduced the price target on its shares to $21 from $27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV. 

Mar
09
Sponsored by
Bio-Rad

This webinar will discuss how next-generation sequencing and digital PCR can be used in a complementary manner for liquid biopsies in order to improve patient care.